ArticleAmerican journal of translational research2024
PIAS family gene expression: implications for prognosis, immunomodulation, and chemotherapy response.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer remains one of the leading causes of mortality worldwide, characterized by uncontrolled cell proliferation and metastasis. Protein Inhibitor of Activated STAT (PIAS) family genes, comprising PIAS1, PIAS2, PIAS3, and PIAS4, are emerging as significant players in cancer biology due to their roles in SUMOylation, transcriptional regulation, and modulation of signal transduction pathways. This study provides a comprehensive analysis of PIAS family genes from a pan-cancer viewpoint. METHODOLOGY: Detailed in silico analyses using publicly available databases and in vitro analyses involving cell culture, gene knockdown, colony formation, and wound healing assays.
resultsExpression analysis revealed consistent up-regulation of PIAS1, PIAS2, PIAS3, and PIAS4 genes in tumors compared to normal tissues. Univariate Cox regression analyses indicate that high PIAS gene expression correlates with worse overall survival in specific cancers, particularly kidney renal papillary cell carcinoma (KIRP) and liver hepatocellular carcinoma (LIHC). Kaplan-Meier plots further confirm that higher PIAS gene expression is significantly associated with reduced survival probabilities in these cancers. Genetic alteration analysis showed low mutation frequencies in PIAS genes, suggesting their role in cancer progression is likely due to expression regulation rather than genetic mutations. Correlations with immune subtypes, the tumor microenvironment (TME), and immune stimulatory genes highlight the differential expression of PIAS genes across immune landscapes in KIRP and LIHC. Gene enrichment analysis emphasizes the involvement of PIAS genes in crucial cellular processes, including SUMOylation and ubiquitin-mediated proteolysis. Finally, knockdown experiments in HCC-LM3 cells demonstrate that PIAS2 and PIAS3 promote tumor growth and metastasis, reinforcing their potential as therapeutic targets.
conclusionThis study revealed the multifaceted roles of PIAS genes in KIRP and LIHC biology and their potential as prognostic biomarkers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.